The comparative efficacy and tolerability of CGP 56697 (artemether+lumefantrine) versus halofantrine in the treatment of uncomplicated falciparum malaria in travellers returning from the Tropics to The Netherlands and France

International Journal of Antimicrobial Agents

Volumn 12, Issue 2, 1999, Pages 159-169

  Van Agtmael, Michiel ^a   Bouchaud, Olivier ^b   Malvy, Denis ^c   Delmont, Jean ^d   Danis, Martin ^e   Barette, Stéphane ^f   Gras, Claude ^g   Bernard, Jacques ^h   Touze, Jean Etienne ^g   Gathmann, Insa ⁱ   Mull, Robert ⁱ  

^a Trop Med AIDS Dept Clin P   (Netherlands)

^b BICHAT HOSPITAL   (France)

^c HÔPITAL SAINT ANDRÉ   (France)

^d Hopital Felix Houphouet Boigny   (France)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^f HIA Desgenettes   (France)

^g LAVERAN MILITARY TEACHING HOSPITAL   (France)

^h F 31000   (France)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Artemether; Benflumetol; CGP 56697; Efficacy; Halofantrine; Lumefantrine; Malaria; QTc; Randomised controlled double blind trial; Riamet; Tolerability; Traveller; Treatment

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; HALOFANTRINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FRANCE; HEADACHE; HEMOLYTIC ANEMIA; HEPATITIS A; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MALE; MULTICENTER STUDY; MYALGIA; NETHERLANDS; ORAL DRUG ADMINISTRATION; PARASITEMIA; PLASMA CLEARANCE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; TRAVEL; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AFRICA; ANIMALS; ANTIMALARIALS; ARTEMISININS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FLUORENES; FRANCE; HUMANS; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; NETHERLANDS; PARASITE EGG COUNT; PHENANTHRENES; PLASMODIUM FALCIPARUM; SESQUITERPENES; TIME FACTORS; TRAVEL; TROPICAL CLIMATE;

EID: 0033038463     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00070-9     Document Type: Article

References (29)

1. Wensdorfer W.H. Epidemiology of drug resistance in malaria. Acta Trop. 56:1994;143-156.
2. Olliaro P.L., Trigg P.I. Status of antimalarial drugs under development. Bull WHO. 73(5):1995;565-571.
3. Watt G., Loesuttiviboon L., Jongsakul K., Shanks G.D., Ohrt C.K., Karnasuta C., Schuster B., Fleckenstein L. Clinical efficacy and tolerance of extended-dose halofantrine for drug-resistant falciparum malaria in Thailand. Am J Trop Med Hyg. 50(2):1994;187-192.
4. Del Nero L., Lamizana L., Ebie I., Sare S., Bougouma L., Pietra V. In vivo sensitivity of Plasmodium falciparum to halofantrine hydrochloride in Burkina Faso. Am J Trop Med Hyg. 50(1):1994;102-106.
5. Bunnag D., Viravan C., Karbwang J., Looareesuwan S., Chittamas S., Harinasuta T., Serville P., Horton J. Clinical trials with halofantrine in acute uncomplicated falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health. 24(1):1993;43-48.
6. Gay F., Bustos M., Diquet B., Rojas-Rivero L., Litaudon M., Pichet C., Danis M., Gentilini M. Cross resistance between mefloquine and halofantrine. Lancet. 336:1990;1262.
7. Rojas-Rivero L., Gay F., Bustos M.D.G., Ciceron L., Pichet C., Danis M., Gentilini M. Mefloquine-halofantrine cross resistance in Plasmodium falciparum induced by intermittent mefloquine pressure. Am J Trop Med Hyg. 47:1992;372-377.
8. Karbwang J., Na Bangchang K. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet. 27:1994;104-119.
9. Tiovonen L., Viitasalo M., Siikamaki H., Raatikka M., Pohjola-Sintonen S. Provocation of ventricular tachycardia by antimalarial drug halofantrine in congenital long QT syndrome. Clin Cardiol. 17:1994;403-404.
10. Monlun E., Le Metayer P., Szwandt S., Neau D., Longy-Boursier M., Horton J., Le Bras M. Cardiac complications of halofantrine: a prospective study of 20 patients. Trans R Soc Trop Med Hyg. 89:1995;430-433.
11. Nosten F., ter Kuile F., Luxemburger C. et al. Cardiac effects of antimalarial treatment with halofantrine. Lancet. 341:1993;1054-1056.
12. White N.J. The treatment of malaria. New Engl J Med. 535:1996;800-806.
13. Hien T.T., White N.J. Qinghaosu. Lancet. 341:1993;603-608.
14. De Vries P.J., Dien T.K. Clinical pharmacology and therapeutic potential of artemisinin and its derivatives in the treatment of malaria. Drugs. 52:1996;818-836.
15. Freedman L.S. Tables of the number of patients required in clinical trials using the log rank test. Statistics Med. 1:1982;121-129.
16. Bazett, 1920. An analysis of time relations of electrocardiograms, Heart, 7, 353-370.
17. Bouchaud O., Basco L.K., Gillotin C., Gimenez F., Ramiliarisoa O., Genissel B., Bouvet E., Farinotti R., le Bras J., Coulaud J.P. Clinical efficacy and pharmacokinetics of micronized halofantrine for the treatment of acute uncomplicated falciparum malaria in nonimmune patients. Am J Trop Med Hyg. 51(2):1994;204-213.
18. Vonseidlein L., Jaffar S., Pinder M., Haywood M., Snounou G., Gemperli B. et al. Treatment of African children with uncomplicated falciparum malaria with a new antimalarial drug, CGP 56697. J Infect Dis. 176:1997;1113-1116.
19. Jiao X., Liu G.Y., Shan C.O., Zhao X., Gathmann I., Royce C. Phase II trial in China of a new, rapidly-acting and effective oral antimalarial CGP 56697 for the treatment of Plasmodium falciparum malaria. Southeast Asian J Trop Med Public Health. 28(3):1998;476-481.
20. Van Vugt M., Brockman A., Gemperli B., Luxemburger C., Gathmann I., Royce C. et al. Randomised comparison of artemether-lumefantrine and artesunate-mefloquine in treatment of multidrug-resistant malaria. Antimicrob Agents Chemother. 42(1):1998;135-139.
21. Ezzet F., Mull R., Karbwang J. Population pharmacokinetics and therapeutic response of CGP 56697 (artemether+benflumetol) in malaria patients. Br J Clin Pharmacol. 46(6):1997;553-561.
22. Bindschedler M, Jiao XQ, Liu ZL et al. Comparative bioavailability of artemether and lumefantrine after single oral administration of CGP 56697 under fed and fasting conditions. XIVth International Congress for Tropical Medicine and Malaria November 17-22, 1996:346 (Abstract).
23. Van Vugt M., Wilairatama P., Gemperli B., Gathmann I., Royce C., Nosten F. et al. Double-blind, randomised trial of standard and high dose regimens of CGP 56697, a new oral antimalarial combination in the treatment of multi-drug resistant Plasmodium falciparum malaria in Thailand. Clin Microbiol Infect (Abstract). 3:1997;181.
24. Matson P.A., Luby S.P., Redd S.C., Rolka H.R., Meriwether R.A. Cardiac effects of standard-dose halofantrine therapy. Am J Trop Med Hyg. 54(3):1996;229-231.
25. Thomas S.H.L. Drugs and the QT interval. Adverse drug reaction bulletin. February. 182:1997;691-694.
26. Sowunmi A., Falade C.O., Oduola A.M.J., Ogundahunsi O.A.T., Fehintola F.A., Gbotosho G.O., Larcier P., Salako L.A. Cardiac effects of halofantrine in children suffering from acute uncomplicated malaria. Trans R Soc Trop Med Hyg. 92:1998;446-448.
27. Brewer T.G., Grate S.J., Peggins J.O., Weina P.J., Petras J.M., Levine B.S. et al. Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg. 51:1994;251-259.
28. White N.J., Olliaro P.L. Strategies for the prevention of antimalarial drug resistance: rationale for combination therapy for malaria. Parasitol Today. 12(10):1998;399-401.
29. Price R.N., Nosten F., Luxemburger C. et al. Effects of artemisinin derivatives on malaria transmissibility. Lancet. 347:1996;1654-1658.